Clinical trial
An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic…
NCT00455429 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Terminated
Key facts
| NCT number | NCT00455429 |
|---|---|
| Title | An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis |
| Official title | A Double-Blind, Randomized, Placebo-Controlled, Sequential Cohort Exploratory Study of the Safety and Efficacy of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis That is Moderate in Severity |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Atopic Dermatitis |
| Intervention type | Drug |
| Interventions | Placebo, JNJ-26113100 (50 mg) once daily, JNJ-26113100 (100 mg) once daily, JNJ-26113100 (100 mg) twice daily, JNJ-26113100 (250 mg) twice daily |
| Enrollment | 84 |
| Start date | Apr 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Apr 3, 2007 |
| Last update posted | Mar 12, 2014 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: